United Therapeutics Corporation Future Amortization Expense, Year Five (Deprecated 2012-01-31)
United Therapeutics Corporation (UTHR) reported Future Amortization Expense, Year Five (Deprecated 2012-01-31) of $475.00 thousand for the 6-month period ending 2012-06-30, per its 10-Q filed 2012-07-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FutureAmortizationExpenseYearFive · last filed 2012-07-26
- United Therapeutics Corporation future amortization expense, year five (deprecated 2012-01-31) for the quarter ending 2012-06-30 was -$375.00K.
- United Therapeutics Corporation future amortization expense, year five (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $850.00K.
- United Therapeutics Corporation future amortization expense, year five (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $150.00K.
- United Therapeutics Corporation future amortization expense, year five (deprecated 2012-01-31) for fiscal 2011 was $1.06M.
| Period end | Future Amortization Expense, Year Five (Deprecated 2012-01-31) 3 month | Future Amortization Expense, Year Five (Deprecated 2012-01-31) 6 month | Future Amortization Expense, Year Five (Deprecated 2012-01-31) 9 month | Future Amortization Expense, Year Five (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-06-30 | -$375.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $475.00K 10-Q · filed 2012-07-26 | $625.00K derived: sum of 3 quarters · filed 2012-07-26 | |
| 2012-03-31 | $850.00K 10-Q · filed 2012-04-26 | $1.00M derived: sum of 2 quarters · filed 2012-04-26 | ||
| 2011-12-31 | $150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $1.06M 10-K · filed 2012-02-28 | ||
| 2011-09-30 | $910.00K 10-Q · filed 2011-10-27 | |||
| 2010-12-31 | $587.00K 10-Q · filed 2011-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |